EUCTR2015-005772-16-DK进行中(未招募)1 期
The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncomplicated appendicitis
Department of Surgery, Herlev Hospital0 个研究点目标入组 14 人开始时间: 2016年2月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Men =18 years old
- •Suspicion of acute appendicitis and planned for diagnostic laparoscopy and eventual appendectomy
- •Written informed consent after written and verbal information
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 13
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •Cannot understand, read or speak Danish
- •Previous allergic reaction to fosfomycin, metronidazole, or GM-CSF
- •Perforated appendicitis (diagnosed either during surgery or at a preoperative computer tomography (CT) scan)
- •Diagnostic laparoscopy revealing normal appendix not requiring an appendectomy
- •Other intra-abdominal pathology requiring surgical intervention (diagnosed either during surgery or at a preoperative CT-scan)
- •Known renal or hepatic disease or biochemical evidence at the time of admission
- •Known autoimmune disease or other chronic inflammation
- •Known hematologic disease or cancer
- •Previous abdominal surgery (either laparoscopic or open surgery)
- •Daily use or use of medication one week prior to or during the trial period apart from painkillers such as paracetamol, ibuprofen, tramadol, and morphine as well as drugs needed for anaesthesia, thrombosis prophylaxis, and nausea. Limitations for antibiotics are defined below
- •Use of other antimicrobial agents than the trial treatment one month before until 24 hours after the trial treatment
- •Participant in another drug trial one month prior to the date of the surgery
- •Body mass index =35 kg/m2
- •Weekly intake of alcohol >14 units, where one unit corresponds to 12 g alcohol
研究者
相似试验
已完成
2 期
Effect evaluation of interaperitoneal injection of bupivacaine on post-operative pain in laparascopic cholecyctectomypost-operative pain in laparascopic cholecyctectomy.Postcholecystectomy syndromeIRCT2012090910790N1Ahwaz Jundishapour University of Medical Sciences60
已完成
1 期
Safety and Pharmacology of CIGB-300 in cervical cancer (CERVIFARM-300 Study)Cervical epidermoid carcinoma, stage IB2-II.RPCEC00000141Center for Genetic Engineering and Biotechnology (CIGB)
已完成
2 期
Evaluation of the effect of intraperitoneal injection of Bupivacain 0.5% in post operation nausea and vomiting in laparascopic cholecystectomyPostcholecystectomy syndromenausea and vomiting resolve after laparscopic cholecystectomy.IRCT201110287928N1Ahvaz Jundishapur University of Medical Science50
进行中(未招募)
不适用
Pharmacokinetical-clinical study of intravescical gemcitabine in patients with marker lesion of superficial transitional cell carcinoma of the bladder - NDPatients with superficial transitional cell carcinoma of the bladderMedDRA version: 6.1Level: PTClassification code 10005003EUCTR2007-001942-42-ITAZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
进行中(未招募)
不适用
Pharmacokinetics, pharmacodynamics and safety of intra-articular multiple doses of 500 mcg icatibant in an uncontrolled 13-week multi-center study in patients with symptomatic knee osteoarthritis - TRICAPEKAEUCTR2006-000763-29-LTSanofi-Aventis Deutschland GmbH12
